peter attia on semaglutide A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% New insights on GLP-1 agonists—Ozempic,

Why Regulatory Compliance Matters Strong compliance programs help organizations: Reduce enforcement risks Improve inspection readiness Strengthen patient safety protections Support business continuity Protect brand reputation Minimize legal exposure Organizations that proactively address regulatory concerns are generally better positioned for sustainable growth

The BBB permeability of ibuprofen-coupled nanocarriers was also tested under pro-inflammatory conditions (Fig

Nguyen T, Gong M, Wen S, Yuan X, Wang C, Jin J, et al

Notably, participants had not reached a weight loss plateau by the end of the 48-week study, suggesting that the full weight loss potential of retatrutide may extend beyond this timeframe